Expands Agilent’s end-to-end biopharma solutions that accelerate drug discovery, development, and manufacturing SANTA CLARA, Calif. — Agilent Technologies Inc. (NYSE: A) today announced it has signed a definitive agreement to acquire BIOVECTRA, a leading specialized contract development and manufacturing organization, for $925 million. Based in Canada, BIOVECTRA produces biologics, highly potent active pharmaceutical ingredients, and […] Read The Rest at :